Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis

Su, Xiaole; Yan, Bingjuan; Wang, Lihua; Lv, Jicheng; Cheng, Hong; Chen, Yipu

doi:10.1053/j.ajkd.2021.02.328

Cited by 32 publications

(31 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The leg and pedal edemas disappeared. Edoxaban exhibits several advantages for the treatment and prevention of venous thromboembolism[ 22 , 23 ]. Especially, it exhibited safety and efficacy when used to treat an over 80- year- old patient with poor renal function.…”

Section: Discussionmentioning

confidence: 99%

Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report

Li¹,

Tian²,

Ma³

et al. 2022

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Polycystic kidney disease (PKD) is a genetic disorder characterized by the growth of numerous cysts within the kidneys. Disease progress of some patients often occurs at the early stage. Thus, managing and controlling disease progress is important to slow the kidney function decline especially for the patient with other disorders. CASE SUMMARY One 80-year-old male autosomal dominant polycystic kidney disease (ADPKD) patient with chronic kidney disease and other clinical disorders was treated with tolvaptan and edoxaban. Estimated glomerular filtration rate, creatinine and uric acid were monitored during the treatment. In addition, the whole exome sequencing was performed to screen ADPKD genetic variants. The kidney function decline was prevented after using tolvaptan and edoxaban treatment and in the meantime, a venous thromboembolism was removed and leg and pedal edema were alleviated. One mutation c.10102G>A /p.D3368N in the PKD1 gene was identified. CONCLUSION Tolvaptan combined with edoxaban administration could delay kidney function decline and eliminate the edema caused by the thromboembolism.

show abstract

Section: Discussionmentioning

confidence: 99%

Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report

Li¹,

Tian²,

Ma³

et al. 2022

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…As described in detail previously, NMA within a Bayesian framework will be conducted to attempt to partly explain the source of heterogeneity in pairwise meta-analysis. 53 Given the inevitable confounding and the availability of data from observational studies, only RCTs will be included in Bayesian NMA for indirect comparisons between different ULTs. In NMA, event numbers and the total population at risk will be extracted from each RCT as original data.…”

Section: Methodsmentioning

confidence: 99%

“…We will use non-informative priors with vague normal (mean, 0; variance, 10 000) and uniform (0–5) prior distributions for parameters such as means and SDs, respectively. 53 54 We will generate 200 000 simulations for each of the two sets of different initial values and discard the first 80 000 simulations as the burn-in period for each analysis. Convergence will be reached when the potential scale reduction factor is close to 1 (using a cut-off of 1.05) for each of the parameters using the Brooks-Gelman-Rubin statistic.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular and kidney outcomes of uric acid-lowering therapy in patients with different kidney functions: study protocol for a systematic review, pairwise and network meta-analysis

et al. 2023

Self Cite

View full text Add to dashboard Cite

IntroductionHyperuricaemia has been implicated in the development of kidney function in populations with chronic kidney disease; however, the benefits of urate-lowering therapy (ULT) remain uncertain in different clinical studies. The different kidney functions of enrolled populations and distinct pharmacokinetic characteristics of ULT might be of the essence for the contrasting results. In this study, we will synthesise all available data from randomised controlled trials (RCTs) and cohort studies, then evaluate the outcomes of ULT in patients stratified by different estimated glomerular filtration rate (eGFR) stratifications. Furthermore, we will attempt to explore a relatively optimal ULT regimen using a Bayesian network meta-analysis in different eGFRs.Methods and analysisWe searched published and unpublished data from MEDLINE, EMBASE, the Cochrane Central Register of Controlled trials and ClinicalTrials.gov website (before March 2022) for RCTs and cohort studies without language restriction. In the pairwise meta-analysis, all regimens of ULT will be pooled as a whole and compared with controls in different eGFRs. The random-effects model will be applied to generate the summary values using the software Stata V.12.0 (StataCorp). Network meta-analysis within a Bayesian framework will be conducted to explore the relative efficacy profiles of different ULTs and to find optimal ULT in different eGFRs. The software of WinBUGS V.1.4.3 and R2WinBUGS package of R V.3.1.1 will be used in the network meta-analysis. Primary outcomes will be the occurrence of major cardiovascular events and kidney failure events. Secondary outcomes will include the rate of change in eGFR per year, all-cause death, changes in serum uric acid level and major adverse events. Two authors will independently review study selection, data extraction and quality assessment.Ethics and disseminationThe meta-analysis does not require ethical certification. The results will be disseminated through publication in a peer-reviewed journal and through presentations at academic conferences.PROSPERO registration numberCRD42021226163.

show abstract

“…Meta-analyses also indicated that NOACs were superior to warfarin in preventing thromboembolic events and lowering the risk for bleeding in individuals with AF and mild to moderate CKD. 18 , 19 In several large observational studies based on Asian populations, all 4 NOACs also showed comparable or lower risk for thromboembolism and a lower risk for bleeding than warfarin in patients with mild to moderate CKD. 20 , 21 …”

Section: Noacs In Patients With Chronic Kidney Diseasementioning

confidence: 99%

Stroke Prevention in Atrial Fibrillation

Chiang

Chao²,

Choi³

et al. 2022

JACC: Asia

View full text Add to dashboard Cite

Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis

Cited by 32 publications

References 81 publications

Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report

Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report

Cardiovascular and kidney outcomes of uric acid-lowering therapy in patients with different kidney functions: study protocol for a systematic review, pairwise and network meta-analysis

Stroke Prevention in Atrial Fibrillation

Contact Info

Product

Resources

About